This is an aggregated industry headline. Read the full story at FierceBiotech →
Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M
Spero Therapeutics is pivoting to immune and inflammation indications through a license agreement for a CD40L antibody with Innovent Biologics in a deal worth up to $1.1 billion.
By FierceBiotech
· Jul 14, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Insulet and Calm are integrating mental health care into diabetes treatment with a series of mindfulness, medi…
The WeekBriefing
Jemperli met its main goal in a phase 2 trial for certain rectal cancers, and GSK now plans to seek U.S. appro…
The WeekSTAT News ↗
A former FDA toxicologist has accused the agency of authorizing Zyn nicotine pouches without fully reviewing t…